Health Care

FDA Approves First Gene Therapy for Spinal Muscular Atrophy

FDA Approves First Gene Therapy for Spinal Muscular Atrophy”

Called Zolgensma, it is a type of cutting-edge, one-time treatment called a "gene therapy" that treats the disease spinal muscular atrophy at its genetic root. The dose administered is decided on based on the weight of the patient.

Around 10,000 to 25,000 USA children and adults are estimated to have the disease, which occurs in one of every 6,000 to 10,000 births.

According to David Lennon of AveXis, there are now around 1,100 patients eligible for treatment with Zolgensma in the US. One version the Energy and Commerce Committee is considering would exclude rare disease treatments from those requirements.

Given the severity of the condition, and Zolgensma's early results, Pearson said insurers would going "cover Zolgensma no matter the price" even when Novartis has publicly floated the idea of a price approaching $5m. Most do not survive past early childhood. The gene encodes the survival motor neuron (SMN) protein - a protein found throughout the body, which is critical for the maintenance and function of specialised nerve cells, called motor neurons.

Peter Marks, director of the FDA's Center for Biologics Evaluation and Research, stated that patients with SMA "now have another treatment option to minimise the progression of SMA and improve survival". Patients treated with the drug also showed significant improvement in their ability to reach developmental motor milestones, such as head control and sitting without support, compared to the natural history of patients with the disease. The company noted that it would provide rebates to insurance companies if the drug is not successful, though it did not offer details about what would be considered failure.

CEO Vas Narasimhan recently signaled that the therapy could be worth more than $5 million, considering the years of intensive care the drug can replace. "It is a positive outcome for patients and the entire health system that Novartis instead chose to price Zolgensma at a level that more fairly aligns with the benefits for these children and their families".

The Institute for Clinical and Economic Review, an independent watchdog group, said that the price of Zolgensma "falls within the upper bound" of its value-based benchmark range, which takes into account the value of increased lifespans.

"The acquisition price was based not on cost to develop the drug but based on expectations of high returns", he said.

This treatment is a breakthrough for Spinal Muscular Atrophy (SMA) patient and expected to be a great relief for patients however; though Novartis claimed it to be cost effective as compared to 10-year cost of current chronic SMA treatment (estimated at United States dollars 4.1 million).But this unique treatment is priced at a whooping price tag of USD 2.125 Million.



Like this

loading...
loading...

Latest


31 Мая 2019
Kushner arrives in Israel as part of a Middle East trip
In response, the 120-member Israeli parliament, the Knesset, voted to dissolve, teeing up a new election for September 17. The Palestinians, who are refusing to engage with the U.S. on the peace plan, delighted in the prospect of its delay.

31 Мая 2019
Holder, captains meet Queen, Prince Harry as World Cup opens
New Zealand were unable to build on their win over India as they were beaten by 91 runs by the West Indies in Bristol. We also didn't know much about them and it was a different challenge.

31 Мая 2019
Flavoring E-cigarettes May Increases the Risk of Cardiovascular Diseases, Says Study
However, this new scientific enquiry is the first to specifically analyse the impact of e-liquids on cardiovascular cells. A paper describing the findings was published online May 27 in the Journal of the American College of Cardiology .

31 Мая 2019
Baseball Team Loses Sponsor Over AOC 'Enemies Of Freedom' Video
The company said in a statement that the decision to pull the sponsorship was not political but rather "the right thing to do". As of Thursday, two additional sponsors have dropped the Grizzlies, they are Dos Equis and Tecate.

31 Мая 2019
Pence in Canada as he looks to build momentum on trade deal
Trump has yet to make a state visit to Canada, which is unusual for a US president in his third year in office. I encourage my colleagues in Canada to address these critical issues before passing the agreement".

31 Мая 2019
Junior forward Sam Hauser announces transfer to Virginia
Unfortunately for many Wisconsin basketball fans, the Hauser brothers are leaving the Badger State to play college ball elsewhere. The 6-foot-8 forward played in 101 games for Marquette, including 97 starting assignments.

31 Мая 2019
New Hampshire Legislature overrides governor's veto and repeals death penalty
Melanie Levesque, a Democrat from Nashua. "We are not those people", she said. "That doesn't happen here in New Hampshire". Sharon Carson, believe that the repeal will be interpreted differently by the courts to prevent the execution of Addison.

31 Мая 2019
Samsung Galaxy M40 to launch on June 11; here're the details
Samsung Galaxy M40 to have a 32MP main sensor for the triple camera and will be priced under Rs 20,000. Previously, Samsung packed in similar sized batteries on their Galaxy M30 and Galaxy M20 devices.

30 Мая 2019
Facebook and Twitter say Iran-based social media scheme impersonated press
In recent months, Facebook also has taken down numerous other Iran-linked fake accounts that it has identified as dubious. Jerry McNerny (D-CA) and Jinea Butler who lost the race for New York's 13th district to Rep.

30 Мая 2019
Lamar Odom's Khloe Kardashian SoulCycle Altercation Revealed in Memoir
Khloe Kardashian's ex Lamar Odom thinks Tristan Thompson was "as stupid as he was" when he kissed Khloe's friend Jordyn Woods . Odom was so high on cocaine and ecstasy one evening, he was hallucinating and Khloe called his friends to intervene. "I hope.